Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013

085293,832419,50267,544Operating expensesResearch and development

(1,953)(2,249)(362)(7,615)(8,459)(1,362)Sales and marketing

(16,567)(26,116)(4,205)(61,678)(93,684)(15,084)General and administrative

(23,086)(26,992)(4,346)(89,696)(108,045)(17,396)Total operating expenses

(41,606)(55,357)(8,913)(158,989)(210,188)(33,842)Operating income34,84250,7478,172134,843209,31433,702Other income/(expense), netInterest income

3,4114,00264413,43215,0642,425Interest expense

(896)(22,070)(3,553)(3,287)(70,097)(11,286)Exchange gain/(loss)

33(25)(4)(1,343)(984)(158)Dividend income

---7,2174,685754Others

82392414973720333Total other income/(expense), net

3,371(17,169)(2,764)16,756(51,129)(8,232)Income before income tax 38,21333,5785,408151,599158,18525,470Income tax expense

(6,597)(10,483)(1,688)(9,634)(38,543)(6,206)Net income31,61623,0953,720141,965119,64219,264Net income attributable to non-

controlling interests

 

(2,377) 

(67) 

(11) 

(9,985) 

(7,195) 

(1,158)Net income attributable tothe Company29,23923,0283,709131,980112,44718,106Net income per share:Attributable to ordinary shares- Basic

0.400.320.051.791.490.24- Diluted

0.400.320.051.791.490.24Other comprehensive income-
Net effect of foreign currency 
translation, net of nil tax

(604)2,936473(1,653)1,296209-
Net unrealized gain/(loss) in
available-for-sale equity securities,
net of nil tax

58,05512,0231,93646,587(9,120)(1,468)Comprehensive income89,06738,0546,129186,899111,81818,005Comprehensive income attributable
to non-controlling interests

(2,427)(67)(11)(10,282)(7,172)(1,155)Comprehensive income 
attributable to the Company 86,64037,9876,118176,617104,64616,850  

 

 


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. RAPS Opens Offices in Singapore and China
2. Research Report on Chinas Diabetes Drug Market, 2013-2017
3. Research Report on Chinas Antidepressant Market, 2013-2017
4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
11. China Cord Blood Corporation Received AABB Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- A n ew ... developing and commercialising innovative medicines to transform patient quality of ... experienced management team; blue chip ... BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces ... gross, from blue chip institutional investors and simultaneously acquired a ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) ... Refrigerators and Freezers Market - Global Industry Analysis, ... 2022" report to their offering. ... has been segmented based on applications: hospitals, research ... The others segment includes applications of biomedical refrigerators ...
(Date:7/28/2015)... -- Kerastem Technologies announce that the Company has received notice ... Biologics Evaluation and Research (CBER) Office of Cellular, Tissue ... the safety and feasibility of the Company,s technology for ... (androgenic alopecia). The phase II study, known ... Europe and Japan ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... Delaware has won a $4.4 million grant from ... Agency (ARPA-E) to lead a multidisciplinary, multi-institutional research ... permanent magnets. Stronger magnets are essential for ... technology, and communications systems in the 21st-century, and ...
... VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... announce third quarter financial results after the market closes ... conference call and live webcast at 4:30 p.m. ET ... the third quarter results. , A live webcast will ...
... Corporation (Nasdaq: DNDN ) today announced that it ... Application (BLA) for PROVENGE ® (sipuleucel-T), the Company,s ... Administration (FDA). Dendreon is seeking licensure for PROVENGE ... If approved by the FDA, PROVENGE would represent the ...
Cached Biology Technology:UD wins $4.4 million to develop next-generation magnets 2OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results 2Dendreon Completes Submission of Biologics License Application for PROVENGE 2Dendreon Completes Submission of Biologics License Application for PROVENGE 3
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... French . , Quebec City, April 15, 2010Researchers ... Center have proven that it is possible to repair the ... by Professor Jacques P. Tremblay, is presenting its new therapeutic ... of the scientific journal Gene Therapy . Duchenne ...
... research team has tested the utility of the short version ... disability in patients with depression, "which in the case of ... of the instrument." In Spain, more than 10% of ... is usually the first to screen an individual who feels ...
... by ESA,s Envisat satellite, shows the vast cloud of volcanic ... more than 1000 km away. Carried by winds high ... eruption of the Eyjafjallajoekull glacier in southwest Iceland has led ... with further disruption in northern Europe expected later today. The ...
Cached Biology News:Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 2It takes only 5 minutes to assess disability in patients with depression 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... Telomerase Detection Kit is a ... for the fluorometric detection and ... activity. It incorporates refinements to ... adds the ability to quantitate ...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
Biology Products: